Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Total Current Liabilities (2023 - 2025)

Guardian Pharmacy Services (GRDN) has disclosed Total Current Liabilities for 3 consecutive years, with $160.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 11.51% to $160.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $160.7 million through Dec 2025, up 11.51% year-over-year, with the annual reading at $160.7 million for FY2025, 11.51% up from the prior year.
  • Total Current Liabilities hit $160.7 million in Q4 2025 for Guardian Pharmacy Services, down from $161.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $161.9 million in Q3 2025 to a low of $138.0 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $150.3 million across 3 years, with a median of $145.3 million in 2025.
  • Biggest YoY gain for Total Current Liabilities was 11.51% in 2025; the steepest drop was 2.29% in 2025.
  • Year by year, Total Current Liabilities stood at $138.0 million in 2023, then increased by 4.42% to $144.1 million in 2024, then increased by 11.51% to $160.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for GRDN at $160.7 million in Q4 2025, $161.9 million in Q3 2025, and $144.0 million in Q2 2025.